Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Robust revenue growth and solid market positioning underscore Boston Scientific's strengths. Operational challenges and ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

“We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.” Boston Scientific increased its full-year ...

Medical-products company Boston Scientific reported third-quarter results before market open Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products ...

Boston Scientific has outperformed the market over the past year thanks to its innovative product pipeline, strategic acquisitions like Farapulse, and strong clinical data that support product ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...